Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP
- PMID: 15897917
- DOI: 10.1038/sj.pcan.4500798
Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP
Abstract
Most tumor cells are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis but sparing to normal cells, thus providing therapeutic potential for clinical use. Some tumor cells are resistant to TRAIL-induced cell death while the sensitivity could be recruited with the existence of some chemical agents. In this study, human prostatic cancer cell line LNCaP was found to be resistant to TRAIL-induced apoptosis while it could be restored to TRAIL sensitivity with combination treatment of low concentration of doxorubicin. TRAIL receptor-1 (DR4) and TRAIL receptor-2 (DR5) were upregulated under the treatment of doxorubicin and verified to be responsible for TRAIL-mediated signal transduction. Furthermore, caspase-8 and caspase-3 were activated and drove their autocleavage into programmed cell death. Interestingly, apoptosis-inhibitory protein c-FLIP, but not Bcl-2 and XIAP was downregulated after doxorubicin treatment. Taken together, these findings suggested that the pathway of cell apoptosis induced by TRAIL was intact but under negative control. Subtoxic concentration of doxorubicin effectively boosted TRAIL sensitivity via depletion of antiapoptotic protein. These findings support the new strategies for killing tumors with TRAIL and chemical agents.
Similar articles
-
Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.Prostate. 2006 Jun 15;66(9):987-95. doi: 10.1002/pros.20421. Prostate. 2006. PMID: 16541419
-
Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.Gynecol Oncol. 2004 Jun;93(3):594-604. doi: 10.1016/j.ygyno.2004.03.029. Gynecol Oncol. 2004. PMID: 15196850
-
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.Prostate. 2002 Dec 1;53(4):286-99. doi: 10.1002/pros.10155. Prostate. 2002. PMID: 12430140
-
Mechanisms of resistance to TRAIL-induced apoptosis in cancer.Cancer Gene Ther. 2005 Mar;12(3):228-37. doi: 10.1038/sj.cgt.7700792. Cancer Gene Ther. 2005. PMID: 15550937 Review.
-
Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.Vitam Horm. 2004;67:453-83. doi: 10.1016/S0083-6729(04)67023-3. Vitam Horm. 2004. PMID: 15110190 Review.
Cited by
-
Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.Cancers (Basel). 2022 Dec 18;14(24):6246. doi: 10.3390/cancers14246246. Cancers (Basel). 2022. PMID: 36551731 Free PMC article. Review.
-
Synergy of BID with doxorubicin in the killing of cancer cells.Oncol Rep. 2015 May;33(5):2143-50. doi: 10.3892/or.2015.3841. Epub 2015 Mar 9. Oncol Rep. 2015. PMID: 25760094 Free PMC article.
-
Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.Oncoimmunology. 2013 Dec 1;2(12):e27058. doi: 10.4161/onci.27058. Epub 2013 Nov 5. Oncoimmunology. 2013. PMID: 24498564 Free PMC article. Review.
-
Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.PLoS One. 2013 Jun 6;8(6):e65145. doi: 10.1371/journal.pone.0065145. Print 2013. PLoS One. 2013. PMID: 23762301 Free PMC article.
-
Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells.Sci Rep. 2017 Jun 19;7(1):3763. doi: 10.1038/s41598-017-03898-0. Sci Rep. 2017. PMID: 28630419 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
